

# Medical Genomics of the Human Immune System For PMK Medical Student Y3

Col. Kitti Buranawuti, MD, FACMG

Medical Genomics Division

Phramongkutklao Hospital College of Medicine



# Content

**B1.4.7 Immunogenetics: MHC structure and function,  
erythrocyte antigens**

**B1.5.5 Diseases of the immune system**

**I. Molecular Immunogenetics**

**II. Clinical Immunogenetics**

# I. Molecular Immunogenetics

# Innate Immunity

Non-specific responses such as phagocytosis

# Adaptive Immunity

Specifically acquired T and B lymphocytic responses  
to particular antigens

# Genes of Key Components of the Adaptive Immune Response

- Major Histocompatibility Complex (MHC)
- Immunoglobulin (Ig)
- T-Cell Antigen Receptor (TCR)

“ Immunoglobulin gene superfamily ”

# MHC Class I Mediated Antigen Presentation








Figure 25-50 Molecular Biology of the Cell 5/e (© Garland Science 2008)

# MHC Class II Mediated Antigen Presentation



# Gene Structure of the Human MHC



◆ **Class I + II → Classical HLA** ◆



# Major Histocompatibility Complex

## MHC region:

- The MHC genomic region, located on the short arm of **chromosome 6 (6p21.3)**
- Contains the HLA (Human Leukocyte Antigen) genes
- At least 200 other genes ( $\approx 40\%$  involved in some aspect of the immune response)
- Spanning  $\approx 3.6$  Mb (Shiina et al, 2009)
- It is the most gene-dense region of the genome ( $\approx 1$  gene/16 kb)
- High levels of polymorphism
- Referred to as the **HLA region** (in humans)





# Major Histocompatibility Complex

## Extended MHC region:

- $\approx$  8 Mb of chromosome 6, containing over 250 protein-coding genes
- This region expands the MHC borders to segments with high linkage disequilibrium with the MHC
- Contains additional genes involved in the immune response (Horton et al, 2004; Shiina et al, 2009)

# MHC / HLA Class

- **Class or loci of HLA genes:**
  - **Classical HLA genes** are the highly polymorphic loci that code for the proteins that present peptides to the T-cell receptors (*HLA-A, -B, -C, -DPA1, -DPB1, -DQA1, -DQB1, -DRB1, -DRA1*) → **Class I, II**
  - **Non-Classical genes** which have reduced polymorphism and do not have a role in peptide presentation. → **Class III**




# HLA allele

- A specific DNA sequence at an HLA gene
- Can be thought of as a haplotype of SNP variants
- There are extraordinarily large numbers of HLA alleles, with **> 12,000 for class I** alleles and **> 4,000 for class II**.

# HLA Haplotype

The combination of alleles at several HLA genes on a single chromosome of a given individual.



# Protein & DNA Variation at HLA Loci

HLA Locus	Antigenic Variants	DNA Variants
HLA-A	25	83
HLA-B	53	186
HLA-C	11	42
HLA-DR	20	221
HLA-DQ	9	49
HLA-DP	6	88

# HLA Function

- **HLA class I** molecules


- Expressed in **most cells**, bind peptides of intracellular origin and present them on the cell surface to the **TCRs of CD8+ T-cells**
- Initiating a **cytotoxic response** if they are recognized as foreign.

- **HLA class II** molecules

- Expressed in **antigen presenting cells**, typically bind peptides of extracellular origin and present them to the **TCRs of CD4+ T-cells**
- Triggering a signaling process that leads to the multiplication of **T-helper cells**
- Leading to the stimulation of **B-cells**, which produce **antibodies** to the antigen that triggered the response.




# Inheritance of HLA Haplotypes



# HLA Allele & Diseases Associations

Ankylosing spondylitis	B27
Reiter syndrome	B27
Acute anterior uveitis	B27
Nacrolepsy	DQ6
Celiac disease	DQ2
Hemochromatosis	A3
Congenital adrenal hyperplasia	Bw47

# Nomenclature of HLA Allele



**N = Null**

**L = Low**


**S = Secreted**

**C = Cytoplasm**


**A = Aberrant**

**Q = Questionable**


# Immunoglobulin (Ig)




# Immunoglobulin Structure




# Ig H Chain Gene Rearrangements



# Ig L Chain Gene Rearrangements



# Genes Controlling Isotype Switching of Antibodies





# Constant Region of the H Chain Controls Antibody Function

---

<b>Ig Isotype</b>	<b>Representative Immunological Functions</b>
<b>M</b>	<b>Complement activation</b>
<b>D</b>	<b>Unknown</b>
<b>G</b>	<b>Complement activation, placental transfer, binding to macrophage Fc receptors</b>
<b>E</b>	<b>High affinity binding to mast cells and basophils to elicit histamine/serotonin release</b>
<b>A</b>	<b>Mucosal membrane immunity</b>

---

# Additional factors contributing to antibody diversity

- **Junctional diversity**

Results from the insertion of additional untemplated nucleotides to double stranded V, D, J sequences undergoing recombination

- **Imprecise joining**

Results from variability in original points of DNA fragmentation in V, D, J sequences undergoing recombination

- **Combinatorial diversity**

Results from the pairing of H and L chains produced by independent gene rearrangement events

# Restricted Expression

- **Isotypic exclusion**

Ig produced by single B cell contains only a single H isotype and a single L isotype

- **Allelic exclusion**

Either the paternal or maternal allele for each H and L chain is expressed within single cell


# Generation of Antibody Diversity

Germline Genes	H	$\kappa$	$\lambda$
V	200	100	100
D	20	-	-
J	6	5	6
V x D x J	$2.4 \times 10^4$	500	600
H x $\kappa$	$1.2 \times 10^7$		
H x $\lambda$	$1.4 \times 10^7$		
Total potential repertoire	$\sim 10^{11}$		


# Immunoglobulin Diversity

- Unique somatic rearrangement of DNA sequence in lymphocyte precursor cells
- Can generate  $\sim 10^{11}$  different antibodies
- Protect against the large array of infectious organisms, toxins, cancer cells

# TH1 Cytokine Mediated Cooperation Between CD4 and CD8 T Cells




# T Cell Receptor (TCR)




# T Cell Receptor Genes


$\beta$ -chain locus TRB@ Chromosome 7q34




TRG@ Chromosome 7p14  $\gamma$ -chain locus



$\alpha$ -chain locus TRA@ and TRD@ Chromosome 14q11.2




$\alpha$ -chain locus TRD@






# T Cell Receptor Gene Rearrangement Patterns




# ABO Red Cell Antigen



# ABO gene

- **Chromosome: 9q34.2**
- **ABO gene is organized in 7 exons**
- **Spans over 19 kb**



- **Base pairs: 1,147**
- **Amino acids: 373**

# ABO Alleles

- **O blood:** deletion of guanine 258 near the N-terminus of the protein which results in a frameshift and translation of an almost entirely different protein

Antigen	Structure	Minimal determinant structure
H		Fuc- $\alpha$ 1 $\rightarrow$ 2-Gal- $\beta$ 1-R
B		Gal- $\alpha$ 1 $\rightarrow$ 3-Gal- $\beta$ 1-R Fuc- $\alpha$ 1 $\rightarrow$ 2
A		GalNAc- $\alpha$ 1 $\rightarrow$ 3-Gal- $\beta$ 1-R Fuc- $\alpha$ 1 $\rightarrow$ 2

● Gal ● GalNAc ● Fuc ● GlcNAc \* : residue could be glucose in case of glycolipids; yellow

- **A, B blood:**
  - The first of the seven **nucleotide substitutions which distinguish the A and B transferases, resides in coding exon 6**; exon 7 contains the other 6 nucleotide substitutions which result in four amino acid substitutions that differentiate the A and B transferases.
  - Among those, substitutions responsible for alterations at two sites (L266M and G268A) determine the A or B specificity of the enzyme (Yamamoto and Hakamori).

## **II. Clinical Immunogenetics**

# When To Suspect a Host Defense Defect?

- Frequent infections
  - Recurrent
  - Persistent, despite therapy
  - Severe
  - Caused by opportunistic pathogens
- Failure to thrive
- Family history

# Immune Defects and Infections

## Adaptive Immune System

- **T cell** or combined defect--viruses, fungi and bacteria; opportunistic pathogens
- **B cell** defect--bacterial; respiratory tract

## Innate Immune System


- **NK cell** defect--virus-infected cells (cancer cells)
- **Granulocyte** defect--staphylococci, other bacteria
- **Macrophage** activation defect--mycobacterial disease
- **Complement** defect (C5-9)--neisserial infections

# Examples of Some Genetically Caused Immunodeficiency Syndromes

Immunodeficiency syndrome	Causative defect	Characteristic immune defect
Severe combined immunodeficiency ( <i>scid</i> )	Several including a defect in the <i>Prkdc</i> DNA repair gene, as well as ADA or PNP deficiencies	No T or B lymphocytes
MHC class I deficiency	<i>Tap</i> gene mutations	No CD8 T cells
MHC class II deficiency	At least five, including a defect in the class II transactivator ( <i>CIITA</i> ) gene	No CD4 T cells
X-linked agammaglobulinemia	<i>Btk</i> tyrosine kinase gene	No B lymphocytes
X-linked hyper-IgM syndrome	Defective CD40 ligand ( <i>Cd40l</i> ) gene	No isotype switching from IgM
Phagocyte deficiencies	Multiple gene defects	Loss of phagocytic activity
Complement deficiencies	Multiple gene defects	Loss of complement activity



# Nine X-Linked Primary Immune Diseases




# Severe Combined Immunodeficiency (SCID)

- Infections in first year
  - severe, persistent despite routine treatment
  - opportunistic pathogens
- Failure to thrive
- Few or absent T cells
  - poor proliferation to mitogens
- Non-functional or absent B cells
  - low Ig's; no specific antibody responses
- Fatal without immune reconstitution


# SCID Genetic Analysis pre-1993

Male



Most patients male;  
predominant X-linked  
gene


Unknown



Adenosine deaminase  
defective in a minority  
of cases

# SCID Genetic Analysis Today


- X-linked SCID most common
- >10 genotypes known
- Specific gene defect can be found in 80%
- Clinical applications:
  - Carrier, prenatal dx
  - Gene therapy
  - Predict response to bone marrow transplant




# SCID Genes

			T	B	NK
• IL2RG	XL	50%	-	+	-
• ADA	AR	14%	-	-	-
• JAK3	AR	7%	-	+	-
• IL7RA	AR	7%	-	+	+
• RAG	AR	<7%	-	-	+
• ARTEMIS	AR	<5%	-	-	+
• CD45	AR	rare	-	+	+
• TCRD (CD3 $\delta$ )	AR	rare	-	+	+
• FOXP1	AR	rare	-	+	+


# X-Linked Inheritance of SCID



# Most Common SCID Presentation: Sporadic Male




# *XSCID IL2RG* Protein: Common Gamma Chain (gc) of Cytokine Receptors







# IL2RG Mutations in XSCID



## IL2RG Domains

-  signal sequence
- C** conserved cysteine
- W** WSXWS box
- TM** transmembrane
- B** box1-box2 domain
-  3' untranslated


## X-linked $\gamma$ -SCID Mutations

- nonsense
- missense
- insertion, frame shift
- ▲ deletion, frame shift
- insertion, in frame
- ▲ deletion, in frame
- \* RNA processing
- ← large deletion
- translation mutations

IL2RGbase, Puck et al.

# Limitations of Bone Marrow Transplant (BMT) Treatment for XSCID

- Most patients lack HLA-matched sibling
- Graft vs. host disease
- Persistent immune defects
  - T cell loss
  - Non-functional host B cells



# Integrating Retrovirus Vectors:

## Backbone

Maloney murine leukemia virus  
Lentivirus



## Envelope


Amphotropic  
Gibbon Ape Leukemia Virus  
Feline Leukemia Virus

## Receptor

PiT-2  
PiT-1  
Neutral aa

## Host range

mouse, dog, primate, human  
human, primate, dog  
human, primate, dog



# XSCID: A Good Pilot Disease for Gene Therapy

- BMT does not cure all patients
- Hematopoietic stem cells, HSC, can be removed, transduced and re-infused
- $\gamma c$  expressed in all blood lineages, not tightly regulated
- No immune elimination of corrected cells
- *In vivo* selective advantage for lymphocytes expressing normal  $\gamma c$  protein
- Success in mouse model

**Gene Therapy for the Treatment of Primary Immune Deficiencies. Kuo CY, Kohn DB  
Curr Allergy Asthma Rep. 2016 May;16(5):39.**

**Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease  
Cavazzana-Calvo M, Hacein-Bey S, deSaint Basile G,  
et al.Science 288 (Apr):669-672, 2000.**

**Gene Therapy for X-Linked Severe Combined Immunodeficiency:  
Where Do We Stand?  
Cavazzana M, Six E, Lagresle-Peyrou C, André-Schmutz I  
Hum Gene Ther. 2016 Feb;27(2):108-16.**

**Sustained Correction of X-Linked Severe Combined Immunodeficiency by ex Vivo Gene Therapy  
Hacein-Bey-Abina S, Le Deist F, Carlier F,  
et al.New Engl J Med (Apr 18):1185-1192, 2002.**

# Adverse Events in French XSCID Gene Therapy Trial

Of 10 infants treated, 9 had excellent immune restoration.

Two developed leukemia 27-30 mo. after treatment.

Pt #4 (age 1 mo): expansion of T cell clone

- Gene therapy vector in reverse orientation intron 1 of *LMO2*, a T-ALL associated transcription factor.
- Other factors: family history of childhood cancer, chickenpox, ch 6:13 translocation.
- Chemotherapy, then allogeneic BMT.

Pt #5 (age 3 mo): expansion of at  $\geq 2$  separate T cell clones

- Vector 5' to *LMO2* in forward orientation
- Chemotherapy

# Agammaglobulinemia

- Recurrent infections starting in infancy
  - Otitis, pneumonia
  - Pyogenic bacteria
- Few or absent B cells; bone marrow contains pre-B cells
- No circulating antibodies


# Agammaglobulinemia Genotypes

- X-Linked (XLA)
  - >80% of cases
  - Males
  - Defect in BTK, B cell tyrosine kinase
- Autosomal Recessive
  - Males and females
  - $\mu$  heavy chain immunoglobulin gene
  - $\lambda 5$  surrogate light chain gene
  - Ig $\alpha$  component of B cell antigen receptor
  - BLNK scaffold adaptor protein for B cell signaling



# X-Linked Hyper IgM Syndrome, CD40 Ligand Deficiency

- Failure of isotype switching; very low IgG, IgA, IgE
- CD40L expressed on activated T cells is essential for B cell activation; T cell defects and neutropenia are also found
- Recurrent bacterial respiratory infections, also PCP pneumonia and hepatobiliary disease
- Autosomal recessive forms of failure to isotype switch have been defined
- Treatment:
  - Early, aggressive management of infections
  - Prophylactic antibiotics
  - Bone marrow transplantation if HLA identical sibling exists



**Thank You & Good Luck !**

